作者: Eloisa Jantus-Lewintre , Rafael Sirera , Silvia Calabuig-Fariñas , Francisco Aparisi , Carlos Camps
关键词: Immunology 、 Immune checkpoint 、 Lung cancer 、 Antibiotics 、 Biomarker (medicine) 、 Progressive disease 、 Blockade 、 Medicine 、 Immunotherapy 、 Gut flora
摘要: Background: The human gut harbors around 1013–1014 microorganisms, collectively referred to as microbiota. Recent studies have found that the microbiota may an impact on interaction between immune regulation and anti-cancer immunotherapies. Methods: In order characterize diversity composition of commensal its relationship with response checkpoint blockade (ICB), 16S ribosomal DNA (rDNA) sequencing was performed 69 stool samples from advanced non-small cell lung cancer (NSCLC) patients prior treatment ICB. Results: use antibiotics ICB-related skin toxicity were significantly associated reduced diversity. However, (ATB) usage not related low ICB efficacy. Phascolarctobacterium enriched in clinical benefit correlated prolonged progression-free survival, whereas Dialister more represented progressive disease, higher relative abundance survival overall independent prognostic value multivariate analysis. Conclusions: Our results corroborate relation baseline outcomes NSCLC patients, provide novel potential predictive biomarkers for immunotherapy NSCLC.